Tvardi Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
1.9%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$2.41next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| TTI-101 Phase 1b/2 REVERT LIVER CANCER Topline Data Release | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly25MTarget: Sufficient to fund operations through clinical readouts and into Q4 2026
Research and Development (R&D) Expenses Quarterly4.9MTarget: Reflects ongoing clinical development of TTI-109 and TTI-101
General and Administrative (G&A) Expenses Quarterly2.1MTarget: Reflects public company transition costs
Watch Items
- TTI-109 Phase 1 Healthy Volunteer Topline DataTrigger: Topline safety, tolerability, and pharmacokinetic dataAction: Announce clinical development strategy based on results
- TTI-101 Phase 1b/2 REVERT LIVER CANCER Topline DataTrigger: Topline efficacy and safety results in hepatocellular carcinoma (HCC)Action: Evaluate full dataset to inform subsequent development and regulatory strategy
- Cash Runway and Capital AllocationTrigger: Cash balance dropping below critical operating levels before Q4 2026Action: Utilize the $200M shelf registration or $12.5M ATM facility to secure additional funding
Research as of 20 Jun 2026